Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology
+$0.39 today
- Market cap
- $999.36M
- Beta
- -1.42
- P/E (TTM)
- -19.3
- EPS (TTM)
- -$2.35
Volume 1.10M
Average 0.87M
GPCR Total Current Assets
All assets expected to be converted to cash or used up within one year.
Structure Therapeutics Inc.NASDAQ: GPCR
Total Current Assets · Q2 FY2026 · quarter ended Jun 2026
Total current assets rises 71.7% from a year ago
Total current assets stood at $1.37B at the end of Q2 FY2026, up 71.7% from a year earlier and down 8.0% from the prior quarter. Over 3 fiscal years it compounded at +156.5% a year.
Context
- Total current assets amounted to 96.3% of total assets at the end of Q2 FY2026, down 1.6 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +71.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.57B USD
- Year-over-year change
- +76.2%
- 4-year CAGR
- +94.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.57B | +76.2% |
| FY2024 | 2024-12-31 | 891.21M | +88.2% |
| FY2023 | 2023-12-31 | 473.61M | +408.8% |
| FY2022 | 2022-12-31 | 93.09M | -14.8% |
| FY2021 | 2021-12-31 | 109.25M | — |
Total Current Assets vs competitors
How GPCR compares with its peers on the latest reported figures
- GPCR's Jun 2026 total current assets of $1.37B is the highest of the 8 companies compared; the peer median is $391.86M.
- Its year-over-year change of +71.7% is the 3rd highest of 7, against a peer median of +23.7%.
- Total current assets amounts to 96.3% of total assets for GPCR, versus a peer median of 98.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.37B | +71.7% | +156.5% | 96.3% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $929.17M | — | — | 76.7% |
| Jun 2026 | $665.8M | +98.6% | +80.3% | 99.7% | |
SEPNSepterna, Inc. | Sep 2026 | $507.35M | +3.2% | +134.4% | 81.9% |
BIOABioAge Labs, Inc. | Mar 2026 | $391.86M | +20.6% | +117.1% | 98.5% |
| Mar 2026 | $379.78M | +26.7% | +48.8% | 90.5% | |
| Mar 2026 | $98.81M | +209.6% | +49.1% | 100.0% | |
| Mar 2026 | $46.32M | +3.7% | -21.0% | 99.9% | |
| Peer median (excluding GPCR) | $391.86M | +23.7% | +64.7% | 98.5% | |
Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 105.31M | 26.09M | 129.79M | 169.51M | 799.62M |
| Short-term Investments | 2M | 64.75M | 337.53M | 714.01M | 646.57M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.25M | 6.29M | 7.69M | 124.11M |
| Total Current Assets | 109.25M | 93.09M | 473.61M | 891.21M | 1.57B |
| Property, Plant & Equipment (Net) | 1.79M | 1.29M | 8.36M | 7.01M | 12.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 111K | 3.46M | 45K | 5.11M | 717K |
| Total Non-current Assets | 1.91M | 4.76M | 8.41M | 12.12M | 13.62M |
| Total Assets | 111.16M | 97.85M | 482.02M | 903.33M | 1.58B |
| Account Payables | 3.48M | 6.01M | 4.74M | 8.02M | 13.86M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 231K | 174K | 356K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.94M | 3.54M | 4.33M | 7.29M | 12.43M |
| Total Current Liabilities | 8.66M | 13.01M | 24.74M | 36.02M | 63.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 3.61M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 166.96M | 199.98M | 298K | 302K | 647K |
| Total Non-current Liabilities | 167.23M | 199.98M | 4.31M | 2.47M | 4.26M |
| Total Liabilities | 175.89M | 212.99M | 29.05M | 38.49M | 67.54M |
| Common Stock | 1K | 1K | 14K | 17K | 21K |
| Retained Earnings | (64.74M) | (116.95M) | (206.57M) | (329.1M) | (470.3M) |
| Accumulated OCI | 0 | (110K) | 521K | 914K | 1.05M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (64.74M) | (115.14M) | 452.97M | 864.84M | 1.52B |
| Total Debt | 621K | 260K | 5.45M | 3.86M | 6.49M |
| Net Debt | (104.68M) | (25.83M) | (124.34M) | (165.65M) | (793.14M) |
Structure Therapeutics Inc.
NASDAQ:GPCR
Intrinsic Alpha fair value
Locked
Current Price
$17.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.